Managed Healthcare Executive2 小时
FDA Accepts sNDA for ZORYVE Cream for Atopic Dermatitis Treatment in Young Children
This once-daily topical treatment is the latest phosphodiesterase-4 (PDE4) inhibitor designed for mild to moderate atopic ...
Managed Healthcare Executive3 小时
FDA Accepts BLA Resubmission for Follicular Lymphoma Drug, Odronextamab
The FDA has accepted the biologics licensing application (BLA) resubmission for odronextamab, a potential treatment for ...
强生起诉三星！仿制药市场争夺战升级
然而，三星Bioepis近日与一家未透露名称的“垂直整合健康集团”达成合作，提前以自有品牌销售其仿制药Pyzchiva，并于本周一正式上市。强生指控此举“明显违反协议”，构成“秘密且故意的违约行为”，可能对Stelara的市场份额造成“不可逆的损害”。
MedImpact Expands Access to Two Biosimilars for Stelara
Pharmacy- and manufacturer-neutral approach offers members access to therapeutically equivalent, lower cost alternativesSAN DIEGO--(BUSINESS WIRE)--MedImpact Healthcare Systems, the nation’s largest ...